Literature DB >> 14722617

Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.

Yoshihide Asano1, Hironobu Ihn, Kenichi Yamane, Masahide Kubo, Kunihiko Tamaki.   

Abstract

The principal effect of TGF-beta1 on mesenchymal cells is its stimulation of ECM synthesis. Previous reports indicated the significance of the autocrine TGF-beta loop in the pathogenesis of scleroderma. In this study, we focused on Smad7 and Smurfs, principal molecules in the negative regulation of TGF-beta signaling, to further understand the autocrine TGF-beta loop in scleroderma. Scleroderma fibroblasts exhibited increased Smad7 levels compared with normal fibroblasts in vivo and in vitro. Smad7 constitutively formed a complex with the TGF-beta receptors, and the inhibitory effect of Smad7 on the promoter activity of human alpha2(I) collagen and 3TP-lux was completely impaired in scleroderma fibroblasts. Furthermore, the protein stability of TGF-beta receptor type I was significantly increased in scleroderma fibroblasts compared with normal fibroblasts. There was no significant difference in Smurf1 and Smurf2 levels between normal and scleroderma fibroblasts, and the transiently overexpressed Smurf1 and/or Smurf2 did not affect TGF-beta receptor type I protein levels in scleroderma fibroblasts. These results indicate that the impaired Smad7-Smurf-mediated inhibitory effect on TGF-beta signaling might contribute to maintaining the autocrine TGF-beta loop in scleroderma fibroblasts. To our knowledge, this is the first report of a disturbed negative regulation of TGF-beta signaling in fibrotic disorders.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14722617      PMCID: PMC310747          DOI: 10.1172/JCI16269

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  36 in total

1.  Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma.

Authors:  M Kubo; H Ihn; K Yamane; K Tamaki
Journal:  Arthritis Rheum       Date:  2001-03

Review 2.  A strategy for determining the pathogenesis of systemic sclerosis. Is transforming growth factor beta the answer?

Authors:  E C Leroy; E A Smith; M B Kahaleh; M Trojanowska; R M Silver
Journal:  Arthritis Rheum       Date:  1989-07

3.  Increased expression of type VI collagen genes in systemic sclerosis.

Authors:  J Peltonen; L Kähäri; J Uitto; S A Jimenez
Journal:  Arthritis Rheum       Date:  1990-12

Review 4.  Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis.

Authors:  C Mauch; T Kreig
Journal:  Rheum Dis Clin North Am       Date:  1990-02       Impact factor: 2.670

Review 5.  The transforming growth factor-beta family.

Authors:  J Massagué
Journal:  Annu Rev Cell Biol       Date:  1990

Review 6.  Immunologic aspects of scleroderma.

Authors:  J H Korn
Journal:  Curr Opin Rheumatol       Date:  1989-12       Impact factor: 5.006

7.  Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast.

Authors:  E C LeRoy
Journal:  J Clin Invest       Date:  1974-10       Impact factor: 14.808

8.  Secretion and binding of transforming growth factor beta by scleroderma and normal dermal fibroblasts.

Authors:  B W Needleman; J Choi; A Burrows-Mezu; J A Fontana
Journal:  Arthritis Rheum       Date:  1990-05

9.  Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta.

Authors:  W D Xu; E C Leroy; E A Smith
Journal:  J Rheumatol       Date:  1991-02       Impact factor: 4.666

10.  Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis.

Authors:  V Falanga; S L Tiegs; S P Alstadt; A B Roberts; M B Sporn
Journal:  J Invest Dermatol       Date:  1987-07       Impact factor: 8.551

View more
  54 in total

1.  Trigenic neural crest-restricted Smad7 over-expression results in congenital craniofacial and cardiovascular defects.

Authors:  Sunyong Tang; Paige Snider; Antony B Firulli; Simon J Conway
Journal:  Dev Biol       Date:  2010-05-08       Impact factor: 3.582

Review 2.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

Review 3.  The role of the ubiquitin-proteasome system in kidney diseases.

Authors:  Hirotaka Fukasawa
Journal:  Clin Exp Nephrol       Date:  2012-06-09       Impact factor: 2.801

Review 4.  The impact of Fli1 deficiency on the pathogenesis of systemic sclerosis.

Authors:  Yoshihide Asano; Andreea M Bujor; Maria Trojanowska
Journal:  J Dermatol Sci       Date:  2010-07-03       Impact factor: 4.563

Review 5.  Recent advances on pathogenesis and therapies in systemic sclerosis.

Authors:  Norihito Yazawa; Manabu Fujimoto; Kunihiko Tamaki
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 6.  Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials.

Authors:  Naoki Iwamoto; Jörg H W Distler; Oliver Distler
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

7.  Smad7 is required for the development and function of the heart.

Authors:  Qian Chen; Hanying Chen; Dawei Zheng; Chenzhong Kuang; Hong Fang; Bingyu Zou; Wuqiang Zhu; Guixue Bu; Ting Jin; Zhenzhen Wang; Xin Zhang; Ju Chen; Loren J Field; Michael Rubart; Weinian Shou; Yan Chen
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

8.  MiR-3606-3p inhibits systemic sclerosis through targeting TGF-β type II receptor.

Authors:  Xiangguang Shi; Qingmei Liu; Na Li; Wenzhen Tu; Ruoyu Luo; Xueqian Mei; Yanyun Ma; Weihong Xu; Haiyan Chu; Shuai Jiang; Zhimin Du; Han Zhao; Liang Zhao; Li Jin; Wenyu Wu; Jiucun Wang
Journal:  Cell Cycle       Date:  2018-09-17       Impact factor: 4.534

9.  Pharmacogenomic predictors of citalopram treatment outcome in major depressive disorder.

Authors:  Firoza Mamdani; Marcelo T Berlim; Marie-Martine Beaulieu; Gustavo Turecki
Journal:  World J Biol Psychiatry       Date:  2013-03-26       Impact factor: 4.132

10.  Simultaneous transforming growth factor beta-tumor necrosis factor activation and cross-talk cause aberrant remodeling response and myocardial fibrosis in Timp3-deficient heart.

Authors:  Zamaneh Kassiri; Virginie Defamie; Mehrdad Hariri; Gavin Y Oudit; Shalini Anthwal; Fayez Dawood; Peter Liu; Rama Khokha
Journal:  J Biol Chem       Date:  2009-07-22       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.